1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Stada Will Continue To Invest To Drive Growth

CEO Peter Goldschmidt Is Seeking Both Organic And Inorganic Expansion

 
• By Dave Wallace

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

Goldschmidt_Peter
Peter Goldschmidt sets out Stada’s strategy • Source: Stada

Over the past year, Stada has made no secret of its appetite to strike major acquisition and partnership deals as part of its growth strategy.

Late last year the firm struck a key European biosimilars deal with Alvotech, covering seven biosimilars “in all key European markets.” (Also see "Alvotech And Stada Make Biosimilars Pact" - Generics Bulletin, 7 November, 2019.) And shortly afterwards, on the consumer healthcare side, the firm reached a $660m agreement with Takeda for a basket of 20 brands in Russia and the Commonwealth of Independent States

More from Strategy

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

More from Business